← Back to screener

OCULAR THERAPEUTIX, INC OCUL

Rank #2502 · Nasdaq · $1.5B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
11.8
P/E
-18.9
P/B
43.14
ROE
-228.2%
Op. Margin
-141.0%
Debt Ratio
403%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -18.9x, P/B 43.14x. Ranks in the top 86% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -228.2%. Ranks in the top 94% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 403%. Ranks in the top 77% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆
Good

Revenue growth of 13.5% year over year. Ranks in the top 27% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2014–$-0.0B$-0.0B$-0.0B–-13
2015–$-0.0B$-0.0B$-0.0B–-42
2016–$-0.0B$-0.0B$-0.1B–-35
2017–$-0.0B$-0.0B$0.1B–39
2018$0.0B$-0.0B$-0.0B$0.1B-2296.033
2019$0.0B$-0.1B$-0.1B$0.1B-3220.171
2020$0.0B$-0.1B$-0.1B$0.0B-2029.9230
2021$0.0B$-0.1B$-0.1B$0.0B-2029.9518
2022$0.0B$-0.1B$-0.2B$-0.0B-361.1-3220
2023$0.0B$-0.1B$-0.0B$0.1B-179.3150
2024$0.1B$-0.1B$-0.1B$0.1B-152.7183
2025$0.1B$-0.1B$-0.1B$0.0B-141.0403

← See the full screener